GSK (GSK) closed at $37.56 in the latest trading session, marking a +0.59% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.43%.

We compare these trends to the stock’s performance during the 2008 recession. Notably, GSK stock has underperformed the broader market in each of the last three years. Returns for the stock were ...

In the latest market close, GSK (GSK) reached $41.90, with a -1.04% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 0.52% for the day.

GSK plc GSK will report its second-quarter earnings on Jul 31, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $9.5 billion and $1.00 per share, respectively.

Additionally, GSK has a PEG Ratio of 1.2 and a Price/Cash Flow ratio of 7.3X. Value investors should also note GSK's Price/Sales ratio of 2X. A company's earnings performance is important for ...

GSK is a rare undervalued stock in the frothy pharmaceutical sector. It's demonstrating strong operating performance and expects record sales for Shingrix this year.

Additionally, GSK has a PEG Ratio of 1.3 and a Price/Cash Flow ratio of 6.8X. Value investors should also note GSK's Price/Sales ratio of 1.9X. A company's earnings performance is important for ...

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.

Hence, let’s take a more factual approach to GSK’s performance and see the current GSK valuation. GSK Q1 2022 results indicated that the biopharma GSK produced £7.1bn and had an adjusted ...